NewsRx

Search our medical news database

Drug Development

Biopharmaceutical company initiates clinical trial of TRX4 for psoriasis

Published in Medical Letter on the CDC and FDA, September 5th, 2004

TolerRx, Inc., a biopharmaceutical company, announced the initiation of a phase 1 trial of its TRX4 monoclonal antibody in subjects with psoriasis.

This phase 1 trial will be a single-dose, dose-escalation study to establish the safety, pharmacokinetic, and pharmacodynamic profile of TRX4. Approximately thirty moderate to severe psoriasis subjects will be enrolled. The clinical trial is being conducted pursuant to an investigational new drug (IND) application filed with the U.S. Food and Drug Administration.

TRX4 is a humanized monoclonal antibody that binds to a receptor found on all mature T cells called CD3, which is involved in normal T cell...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook